145 related articles for article (PubMed ID: 18363522)
1. Vinflunine: clinical perspectives of an emerging anticancer agent.
Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
Lobert S; Puozzo C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
[TBL] [Abstract][Full Text] [Related]
3. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine: a new microtubule inhibitor agent.
Bennouna J; Delord JP; Campone M; Nguyen L
Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163
[TBL] [Abstract][Full Text] [Related]
5. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Bellmunt J; Delgado FM; George C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of vinflunine: effector pathways and potential for synergies.
Braguer D; Barret JM; McDaid H; Kruczynski A
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S13-21. PubMed ID: 18538174
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine: a novel antitubulin agent in solid malignancies.
Bennouna J; Campone M; Delord JP; Pinel MC
Expert Opin Investig Drugs; 2005 Oct; 14(10):1259-67. PubMed ID: 16185168
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Delord JP; Ravaud A; Bennouna J; Fumoleau P; Favrel S; Pinel MC; Ferré P; Saliba F
Invest New Drugs; 2013 Jun; 31(3):724-33. PubMed ID: 22996801
[TBL] [Abstract][Full Text] [Related]
10. Vinflunine.
Shnyder SD
IDrugs; 2004 Sep; 7(9):851-9. PubMed ID: 15470603
[TBL] [Abstract][Full Text] [Related]
11. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy.
Gerullis H
Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647
[TBL] [Abstract][Full Text] [Related]
12. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
Hill BT
Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
[TBL] [Abstract][Full Text] [Related]
13. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
[TBL] [Abstract][Full Text] [Related]
14. Vinflunine for the treatment of non-small cell lung cancer.
Genova C; Alama A; Coco S; Rijavec E; Dal Bello MG; Vanni I; Biello F; Barletta G; Rossi G; Grossi F
Expert Opin Investig Drugs; 2016 Dec; 25(12):1447-1455. PubMed ID: 27771969
[TBL] [Abstract][Full Text] [Related]
15. Vinflunine.
Frampton JE; Moen MD
Drugs; 2010 Jul; 70(10):1283-93. PubMed ID: 20568834
[TBL] [Abstract][Full Text] [Related]
16. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
17. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Cortes J; Perez-Garcia J; Levy C; Gómez Pardo P; Bourgeois H; Spazzapan S; Martínez-Jañez N; Chao TC; Espié M; Nabholtz JM; Gonzàlez Farré X; Beliakouski V; Román García J; Holgado E; Campone M
Ann Oncol; 2018 Apr; 29(4):881-887. PubMed ID: 29481630
[TBL] [Abstract][Full Text] [Related]
18. Vinflunine for the treatment of breast cancer.
Gourmelon C; Bourien H; Augereau P; Patsouris A; Frenel JS; Campone M
Expert Opin Pharmacother; 2016 Sep; 17(13):1817-23. PubMed ID: 27484180
[TBL] [Abstract][Full Text] [Related]
19. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
20. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.
Isambert N; Delord JP; Tourani JM; Fumoleau P; Ravaud A; Pinel MC; Petain A; Nguyen T; Nguyen L
Br J Clin Pharmacol; 2014 Mar; 77(3):498-508. PubMed ID: 24283925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
